Spectrum Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Spectrum Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-13.8%
Buyback Yield
| Total Shareholder Yield | -13.8% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 14
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates
May 12Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
Sep 20Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
Sep 16Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection
Sep 09Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'
Aug 21Spectrum Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Jun 04Spectrum Pharmaceuticals: Some Last Words
Feb 25Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Oct 05Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Aug 12Spectrum's Big Approval: Any Day Now
Jul 29FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS
Jun 01Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
May 31We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
Feb 12Spectrum Pharma drops after announcing less-than-favorable Phase 2 data
Dec 22Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like
Dec 21Spectrum Pharma Is Down But Not Out
Nov 16Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib
Nov 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SPPI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPPI's dividend payments have been increasing.
Dividend Yield vs Market
| Spectrum Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SPPI) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (SPPI) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate SPPI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPPI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SPPI's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SPPI has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/02 20:25 |
| End of Day Share Price | 2023/07/31 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spectrum Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Auriga USA LLC |
| David Buck | B. Riley Securities, Inc. |
| Alethia Young | Cantor Fitzgerald & Co. |